Mylan releases antifungal generic
CANONSBURG – Mylan N.V. on Monday announced the U.S. launch of Caspofungin Acetate for Injection, one of the first generic versions of Merck’s Cancidas®.
Southpointe-based Mylan said in a press release it received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for the antifungal which has multiple indications.
Caspofungin Acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: empirical therapy for presumed fungal infections in febrile, neutropenic patients; treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections; treatment of esophageal candidiasis; and treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
The medicine had U.S. sales of approximately $24 million for the 12 months ending July 31, according to QuintilesIMS.